Sun Pharmaceutical Receives EMA Support For Cancer Drug Application
Sun received the recommendations in concurrence with the Sanofi-Aventis’s suit in the US against it, claiming that it is a case of infringement of patent and asking the
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).